{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:58:38Z","timestamp":1776326318050,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Relapsed\/refractory peripheral T\u2010cell lymphomas (PTCL) have a poor prognosis. We aimed at assessing efficacy of ifosfamide, carboplatin, etoposide (ICE) regimen, a known therapeutic option, to which we added brentuximab\u2010vedotin (BV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we retrospectively analyzed patients with PTCL treated with BV\u2010ICE in our center between July 2014 and March 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen patients received BV\u2010ICE. Median age was 62\u00a0years (range, 31\u201073). Main histological subtypes were PTCL\u2010not otherwise specified (29%), angioimmunoblastic T\u2010cell lymphoma (21%), follicular\u2010T helper (21%), or anaplastic large\u2010cell (15%) lymphomas, all were CD30 positive. Overall response was seen in four (29%) patients, and complete response (CR) in two (14%). Most frequent adverse events were infections, and cytopenia. 2\u2010year progression\u2010free and overall survival were 14% and 17.5%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with relapsed\/refractory PTCL treated with BV\u2010ICE can achieve CR, but few had a sustained response. This association should preferably be used as a bridge to stem cell transplant or be followed by maintenance therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13568","type":"journal-article","created":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T03:23:07Z","timestamp":1608434587000},"page":"467-472","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Combination of brentuximab\u2010vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T\u2010cell lymphoma"],"prefix":"10.1111","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-2823","authenticated-orcid":false,"given":"Zo\u00e9","family":"Van de Wyngaert","sequence":"first","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"},{"name":"Centre de R\u00e9f\u00e9rence des Microangiopathies thrombotiques AP\u2010HP.6 Paris France"},{"name":"INSERM UMRS 1138 Centre de Recherche des Cordeliers Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Cervera","sequence":"additional","affiliation":[{"name":"Anatomo\u2010pathologie H\u00f4pital Saint Antoine APHP Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Anatomo\u2010pathologie H\u00f4pital Saint Antoine APHP Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Paule","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Corre","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zora","family":"Marjanovic","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek","family":"Aoudjhane","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[{"name":"H\u00e9matologie clinique et th\u00e9rapie cellulaire H\u00f4pital Saint Antoine APHP Sorbonne Universit\u00e9 INSERM UMRs 938 Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084913"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-584953"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: Brentuximab Vedotin in first\u2010line treatment of peripheral T\u2010Cell lymphoma","volume":"5","author":"Richardson NC","year":"2019","journal-title":"Oncologist"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187617"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25463"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701788098"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1738-9"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T17:32:17Z","timestamp":1693675937000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/ejh.13568"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13568","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"assertion":[{"value":"2020-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}